Daunorubicin for the treatment of acute myeloid leukemia

Bibliography

• Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341(14):1051-62
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114(5):937-51
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352(3):254-66
   PubMed Web of Science ®Google Scholar
• Bullinger L, Dohner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004;350(16):1605-16
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107(9):3481-5
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 1998;92(7):2322-33
   PubMed Web of Science ®Google Scholar
• Mrozek K. Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol 2008;35(4):365-77
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115(3):453-74
   PubMed Web of Science ®Google Scholar
• Hiddemann W. Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens. Ann Hematol 1991;62(4):119-28
   PubMed Web of Science ®Google Scholar
• Reese ND, Schiller GJ. High-dose cytarabine (HD AraC) in the treatment of leukemias: a review. Curr Hematol Malig Rep 2013;8(2):141-8
   PubMed Web of Science ®Google Scholar
• Bornstein RS, Theologides A, Kennedy BJ. Daunorubicine in acute myelogenous leukemia in adults. Jama 1969;207(7):1301-6
   PubMed Web of Science ®Google Scholar
• Bernard J, Boiron M. Current status: treatment of acute leukemia. Semin Hematol 1970;7(4):427-40
   PubMed Web of Science ®Google Scholar
• (EORTC) LaHCGotEOfRotToC. Rubidomycin (or Daunomycin): a clinical evaluation. advances in the treatment of acute (Elastic)leukemias. Springer-Verlag, New York; 1970. p. 9-13
   Google Scholar
• Wiernik PH, Serpick AA. A randomized clinical trial of daunorubicin and a combination of prednisone, vincristine, 6-mercaptopurine, and methotrexate in adult acute nonlymphocytic leukemia. Cancer Res 1972;32(10):2023-6
   PubMed Web of Science ®Google Scholar
• Yates JW, Wallace HJ Jr, Ellison RR, et al. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 1973;57(4):485-8
   PubMedGoogle Scholar
• Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 1981;58(6):1203-12
   PubMed Web of Science ®Google Scholar
• Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982;60(2):454-62
   PubMed Web of Science ®Google Scholar
• Hewlett J, Kopecky KJ, Head D, et al. A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): a Southwest Oncology Group study. Leukemia 1995;9(4):562-9
   PubMed Web of Science ®Google Scholar
• Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;88(8):2841-51
   PubMed Web of Science ®Google Scholar
• Rowe JM, Tallman MS. Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged? Blood 1997;90(6):2121-6
   PubMed Web of Science ®Google Scholar
• Kolitz JE, George SL, Baer MR, et al. P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults. Ann Hematol 2004;83(Suppl 1):S103-4
   PubMedGoogle Scholar
• Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361(13):1249-59
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361(13):1235-48
   PubMed Web of Science ®Google Scholar
• Padron E, Fernandez H. Anthracycline dose intensification in young adults with acute myeloid leukemia. Ther Adv Hematol 2012;3(1):17-27
   PubMedGoogle Scholar
• Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366(12):1079-89
   PubMed Web of Science ®Google Scholar
• Cagnetta A, Adamia S, Acharya C, et al. Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. Leuk Res 2014;38(6):649-59
   PubMed Web of Science ®Google Scholar
• Zunino F, Gambetta R, DiMarco A, et al. Effects of the stereochemical configuration on the interaction of some daunomycin derivatives with DNA. Biochem Biophys Res Commun 1976;69(3):744-50
   PubMed Web of Science ®Google Scholar
• Supino R, Necco A, Dasdia T, et al. Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin. Cancer Res 1977;37(12):4523-8
   PubMed Web of Science ®Google Scholar
• Plumbridge TW, Brown JR. Studies on the mode of interaction of 4’-epi-adriamycin and 4-demethoxy-daunomycin with DNA. Biochem Pharmacol 1978;27(14):1881-2
   PubMed Web of Science ®Google Scholar
• Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991;77(8):1666-74
   PubMed Web of Science ®Google Scholar
• Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 1992;10(7):1103-11
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;79(2):313-19
   PubMed Web of Science ®Google Scholar
• Group ac. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. Br J Haematol 1998;103(1):100-9
   PubMed Web of Science ®Google Scholar
• Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103(2):479-85
   PubMed Web of Science ®Google Scholar
• Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010;28(5):808-14
   PubMed Web of Science ®Google Scholar
• Gardin C, Chevret S, Pautas C, et al. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. J Clin Oncol 2013;31(3):321-7
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Ogawa M. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. Cancer Chemother Pharmacol 1982;8(2):157-62
   PubMed Web of Science ®Google Scholar
• Estey EH, Keating MJ, McCredie KB, et al. Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep 1983;67(4):389-90
   PubMedGoogle Scholar
• Koeller J, Eble M. Mitoxantrone: a novel anthracycline derivative. Clin Pharm 1988;7(8):574-81
   PubMedGoogle Scholar
• Arlin Z, Case DC Jr, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Leukemia 1990;4(3):177-83
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Seiter K, Traganos F, et al. Phase II evaluation of a high-dose mitoxantrone based induction regimen in untreated adults with acute myeloid leukemia. Leuk Lymphoma 2000;38(3-4):309-15
   PubMed Web of Science ®Google Scholar
• Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 2009;27(32):5397-403
   PubMed Web of Science ®Google Scholar
• Visani G, Rosti G, Bandini G, et al. Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. Br J Haematol 2000;109(4):722-8
   PubMed Web of Science ®Google Scholar
• Advani R, Saba HI, Tallman MS, et al. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 1999;93(3):787-95
   PubMed Web of Science ®Google Scholar
• Hasinoff BB, Kuschak TI, Fattman CL, et al. The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase II. Anticancer Drugs 1998;9(5):465-71
   PubMed Web of Science ®Google Scholar
• Lubieniecka JM, Graham J, Heffner D, et al. A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor. Front Genet 2013;4:231
   PubMedGoogle Scholar
• Holmes J, Jacobs A, Carter G, et al. Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia. Br J Haematol 1989;72(1):40-4
   PubMed Web of Science ®Google Scholar
• Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol 2000;12(5):450-8
   PubMed Web of Science ®Google Scholar
• Chauncey TR. Drug resistance mechanisms in acute leukemia. Curr Opin Oncol 2001;13(1):21-6
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361-98
   PubMed Web of Science ®Google Scholar
• Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 1987;316(22):1388-93
   PubMed Web of Science ®Google Scholar
• Marie JP. Drug resistance in hematologic malignancies. Curr Opin Oncol 2001;13(6):463-9
   PubMed Web of Science ®Google Scholar
• Den Boer ML, Pieters R, Veerman AJ. Mechanisms of cellular anthracycline resistance in childhood acute leukemia. Leukemia 1998;12(11):1657-70
   PubMed Web of Science ®Google Scholar
• Escriba PV, Ferrer-Montiel AV, Ferragut JA, et al. Role of membrane lipids in the interaction of daunomycin with plasma membranes from tumor cells: implications in drug-resistance phenomena. Biochemistry 1990;29(31):7275-82
   PubMed Web of Science ®Google Scholar
• Le Moyec L, Tatoud R, Degeorges A, et al. Proton nuclear magnetic resonance spectroscopy reveals cellular lipids involved in resistance to adriamycin and taxol by the K562 leukemia cell line. Cancer Res 1996;56(15):3461-7
   PubMed Web of Science ®Google Scholar
• Michieli M, Damiani D, Michelutti A, et al. Overcoming PGP-related multidrug resistance. The cyclosporine derivative SDZ PSC 833 can abolish the resistance to methoxy-morpholynil-doxorubicin. Haematologica 1996;81(4):295-301
   PubMed Web of Science ®Google Scholar
• Michieli M, Damiani D, Ermacora A, et al. Liposome encapsulated daunorubicin doubles anthracycline toxicity in cell lines showing a non-PGP related multidrug resistance. Haematologica 1999;84(12):1151-2
   PubMed Web of Science ®Google Scholar
• Marie JP, Zittoun R. Chemotherapy of acute myelogenous leukaemia. Baillieres Clin Haematol 1991;4(1):97-113
   PubMedGoogle Scholar
• Visani G, Bernasconi P, Boni M, et al. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia – analysis of 848 patients. Leukemia 2001;15(6):903-9
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kreutzmann H, Straif K, et al. Phase I/II trial of high-dose cytosine arabinoside and mitoxantrone in adult refractory acute myeloid leukemia. Haematol Blood Transfus 1987;30:336-8
   PubMedGoogle Scholar
• Visani G, Milligan D, Leoni F, et al. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. Leukemia 2001;15(5):764-71
   PubMed Web of Science ®Google Scholar
• Rao VV, Dahlheimer JL, Bardgett ME, et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 1999;96(7):3900-5
   PubMed Web of Science ®Google Scholar
• Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997;89(13):917-31
   PubMedGoogle Scholar
• Raha A, Tew KD. Glutathione S-transferases. Cancer Treat Res 1996;87:83-122
   PubMedGoogle Scholar
• O’Brien ML, Tew KD. Glutathione and related enzymes in multidrug resistance. Eur J Cancer 1996;32A(6):967-78
   PubMed Web of Science ®Google Scholar
• Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994;54(16):4313-20
   PubMed Web of Science ®Google Scholar
• Keizer HG, Pinedo HM, Schuurhuis GJ, et al. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 1990;47(2):219-31
   PubMed Web of Science ®Google Scholar
• Jedlitschky G, Leier I, Buchholz U, et al. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 1996;56(5):988-94
   PubMed Web of Science ®Google Scholar
• Rappa G, Lorico A, Flavell RA, et al. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res 1997;57(23):5232-7
   PubMed Web of Science ®Google Scholar
• Wada M, Bartram CR, Nakamura H, et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 1993;82(10):3163-9
   PubMed Web of Science ®Google Scholar
• Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994;84(9):3148-57
   PubMed Web of Science ®Google Scholar
• Gieseler F, Glasmacher A, Kampfe D, et al. Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines. Leukemia 1996;10(7):1177-80
   PubMed Web of Science ®Google Scholar
• Michieli M, Michelutti A, Damiani D, et al. A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives. Leuk Lymphoma 1993;9(3):255-64
   PubMed Web of Science ®Google Scholar
• Latagliata R, Breccia M, Fazi P, et al. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br J Haematol 2008;143(5):681-9
   PubMed Web of Science ®Google Scholar
• Hinman LM, Hamann PR, Wallace R, et al. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res 1993;53(14):3336-42
   PubMed Web of Science ®Google Scholar
• Sievers EL. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin Biol Ther 2001;1(5):893-901
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Martinelli G, Rondoni M, et al. First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leuk Res 2004;28(9):987-90
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Martinelli G, Rondoni M, et al. Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. Leuk Lymphoma 2004;45(9):1791-5
   PubMed Web of Science ®Google Scholar
• Candoni A, Martinelli G, Toffoletti E, et al. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Leuk Res 2008;32(12):1800-8
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Culligan D, et al. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. Br J Haematol 2013;158(4):519-22
   Web of Science ®Google Scholar
• Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012;379(9825):1508-16
   PubMed Web of Science ®Google Scholar
• Delaunay J, Recher C, Pigneux A. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR Study. Blood 2011(118):abstract 79
   Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012;30(32):3924-31
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011;29(4):369-77
   PubMed Web of Science ®Google Scholar
• Laszlo GS, Gudgeon CJ, Harrington KH, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 2014;123(4):554-61
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111(3):1060-6
   PubMed Web of Science ®Google Scholar
• Klimek VM, Fircanis S, Maslak P, et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 2008;14(3):826-32
   PubMed Web of Science ®Google Scholar
• Odenike OM, Alkan S, Sher D, et al. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res 2008;14(21):7095-101
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Tambaro FP, Bekele NB, et al. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol 2013;30(18):2204-10
   Web of Science ®Google Scholar
• Gojo I, Tan M, Fang HB, et al. Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Clin Cancer Res 2013;19(7):1838-51
   PubMed Web of Science ®Google Scholar
• Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007;25(25):3884-91
   PubMed Web of Science ®Google Scholar
• Cashen AF, Schiller GJ, O’Donnell MR, et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010;28(4):556-61
   PubMed Web of Science ®Google Scholar
• Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010;107(16):7473-8
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2013;30(21):2670-7
   Web of Science ®Google Scholar
• Ciftci O, Ullrich O, Schmidt CA, et al. Regulation of the nuclear proteasome activity in myelomonocytic human leukemia cells after Adriamycin treatment. Blood 2001;97(9):2830-8
   PubMed Web of Science ®Google Scholar
• Brach MA, Kharbanda SM, Herrmann F, et al. Activation of the transcription factor kappa B in human KG-1 myeloid leukemia cells treated with 1-beta-D-arabinofuranosylcytosine. Mol Pharmacol 1992;41(1):60-3
   PubMed Web of Science ®Google Scholar
• Maestre N, Tritton TR, Laurent G, et al. Cell surface-directed interaction of anthracyclines leads to cytotoxicity and nuclear factor kappaB activation but not apoptosis signaling. Cancer Res 2001;61(6):2558-61
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23(3):630-9
   PubMed Web of Science ®Google Scholar
• Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4(5):349-60
   PubMed Web of Science ®Google Scholar
• Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001;98(8):2301-7
   PubMed Web of Science ®Google Scholar
• Guzman ML, Swiderski CF, Howard DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 2002;99(25):16220-5
   PubMed Web of Science ®Google Scholar
• Attar EC, De Angelo DJ, Supko JG, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 2008;14(5):1446-54
   PubMed Web of Science ®Google Scholar
• Attar EC, Johnson JL, Amrein PC, et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol 2013;31(7):923-9
   PubMed Web of Science ®Google Scholar
• Perl AE, Kasner MT, Tsai DE, et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 2009;15(21):6732-9
   PubMed Web of Science ®Google Scholar
• Recher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005;105(6):2527-34
   PubMed Web of Science ®Google Scholar
• Amadori S, Stasi R, Martelli AM, et al. Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). Br J Haematol 2012;156(2):205-12
   PubMed Web of Science ®Google Scholar
• Park S, Chapuis N, Saint Marcoux F, et al. A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. Leukemia 2013;27(7):1479-86
   PubMed Web of Science ®Google Scholar
• Grunwald MR, Levis MJ. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol 2013;97(6):683-94
   PubMed Web of Science ®Google Scholar
• Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009;113(26):6567-71
   PubMed Web of Science ®Google Scholar
• Sharma M, Ravandi F, Bayraktar UD, et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant 2011;17(12):1874-7
   PubMed Web of Science ®Google Scholar
• Metzelder SK, Schroeder T, Finck A, et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia 2012;26(11):2353-9
   PubMed Web of Science ®Google Scholar
• O’Farrell AM, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003;9(15):5465-76
   PubMed Web of Science ®Google Scholar
• Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105(3):986-93
   PubMed Web of Science ®Google Scholar
• Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105(1):54-60
   PubMed Web of Science ®Google Scholar
• Fischer T, Stone RM, Deangelo DJ, et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010;28(28):4339-45
   PubMed Web of Science ®Google Scholar
• Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006;108(10):3262-70
   PubMed Web of Science ®Google Scholar
• Cortes JE, Perl AE, Dombret H, et al. Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia. ASH Annual Meeting Abstracts, Atlanta, GA; 2012. 120(21 %U http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/1483 %8 November 16, 2012) abstract48
   Google Scholar
• Levis MJ, Perl AE, Dombret H, et al. Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation. ASH Annual Meeting Abstracts, Atlanta, GA; 2012. 120(21 %U http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/1483 %8 November 16, 2012) abstract673
   Google Scholar
• Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28(11):1856-62
   PubMed Web of Science ®Google Scholar
• Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 2013;31(25):3110-18
   PubMed Web of Science ®Google Scholar
• Fiedler W, Kayser S, Kebenko M, et al. Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653). ASH Annual Meeting Abstracts, Atlanta, GA; 2012. 120(21 %U http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;120/21/1483 %8 November 16, 2012) abstract1483
   Google Scholar
• Stone RM, Fischer T, Paquette R, et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 2012;26(9):2061-8
   PubMed Web of Science ®Google Scholar
• Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011;117(12):3294-301
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Malagola M, Rondoni M, et al. Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study. Haematologica 2007;92(12):1721-2
   PubMed Web of Science ®Google Scholar
• .Lancet JE, Gojo I, Burton M, et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 2010;24(4):699-705
   PubMed Web of Science ®Google Scholar
• Huang Y, Wolf S, Beck B, et al. Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities. ACS Chem Biol 2014;9(3):802-11
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013;369(2):111-21
   PubMed Web of Science ®Google Scholar